Flublok Quadrivalent

BIOLOGICAL4 trials

Sponsors

Protein Sciences Corporation, Novavax, Kaiser Permanente, Fatimah Dawood

Conditions

Acute Myocardial InfarctionCongestive Heart FailureInfluenzaInfluenza, HumanLower Respiratory Tract InfectionPneumoniaStroke

Phase 2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

TerminatedNCT03658629

NovavaxInfluenza, Human

Start: 2018-09-24End: 2019-04-26Updated: 2022-11-04

Phase 3

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

CompletedNCT02290509

Protein Sciences CorporationInfluenza

Start: 2014-10-31End: 2015-05-31Updated: 2016-10-27

Phase 4

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

TerminatedNCT05514002

Fatimah DawoodInfluenza, Human

Start: 2022-09-13End: 2023-12-31Updated: 2025-03-24

Unknown Phase

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

CompletedNCT03694392

Kaiser PermanenteAcute Myocardial Infarction, Congestive Heart Failure, Influenza +3

Start: 2018-09-16End: 2022-12-31Updated: 2025-04-08

Related Papers

Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18–64 Years: Results and Experience From a Randomized, Double-Blind Trial

Open Forum Infectious Diseases2024-09-268 citations

Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants.

2024-09-204 citations

Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age

New England Journal of Medicine2023-12-1346 citations

2322. Effectiveness of Recombinant Influenza Vaccine vs. Standard Dose Inactivated Influenza Vaccines Against Hospitalized Influenza-Related Outcomes in Adults: A Cluster Randomized Trial

Open Forum Infectious Diseases2022-12-013 citations

Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.

2022-01-062 citations

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

Clinical Infectious Diseases2020-10-2940 citations